[go: up one dir, main page]

GT201200275A - Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores - Google Patents

Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores

Info

Publication number
GT201200275A
GT201200275A GT201200275A GT201200275A GT201200275A GT 201200275 A GT201200275 A GT 201200275A GT 201200275 A GT201200275 A GT 201200275A GT 201200275 A GT201200275 A GT 201200275A GT 201200275 A GT201200275 A GT 201200275A
Authority
GT
Guatemala
Prior art keywords
robo1
fusion protein
tumor treatment
protein
slit
Prior art date
Application number
GT201200275A
Other languages
English (en)
Inventor
Blanche Francis
Cameron Béatrice
Dabdoubi Tarik
Dol-Gleizes Frédérique
Fons Pierre
Herault Jean-Pascal
Prades Catherine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42830780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201200275(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201200275A publication Critical patent/GT201200275A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA PROTEÍNA RECOMBINANTE ROBO1FC Y SU UTILIZACIÓN PARA TRATAR LAS ENFERMEDADES EN LAS QUE SE SOBREEXPRESA UNA PROTEÍNA SLIT, PARTICULARMENTE CÁNCER. SE REFIERE IGUALMENTE A UNA COMPOSICION QUE COMPRENDE TAL PROTEÍNA RECOMBINANTE. OTRO ASPECTO DE LA INVENCIÓN CONSISTE EN LA UTILIZACIÓN DE UNA MOLÉCULA ROBO1-FC COMO HERRAMIENTA DE DIAGNÓSTICO PARA DETECTAR LA SOBREEXPRESIÓN DE UNA MOLÉCULA DE LA FAMILIA SLIT EN UN PACIENTE.
GT201200275A 2010-04-14 2012-10-11 Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores GT201200275A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1052829A FR2958936A1 (fr) 2010-04-14 2010-04-14 Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs

Publications (1)

Publication Number Publication Date
GT201200275A true GT201200275A (es) 2014-01-24

Family

ID=42830780

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201200275A GT201200275A (es) 2010-04-14 2012-10-11 Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores

Country Status (27)

Country Link
US (1) US9493529B2 (es)
EP (1) EP2558489A1 (es)
JP (1) JP5858442B2 (es)
KR (1) KR20130059329A (es)
CN (1) CN102884076A (es)
AR (1) AR080891A1 (es)
AU (1) AU2011239839B2 (es)
BR (1) BR112012026020A2 (es)
CA (1) CA2796303A1 (es)
CL (1) CL2012002879A1 (es)
CR (1) CR20120508A (es)
DO (1) DOP2012000265A (es)
EA (1) EA201291044A1 (es)
EC (1) ECSP12012230A (es)
FR (1) FR2958936A1 (es)
GT (1) GT201200275A (es)
IL (1) IL222382A (es)
MA (1) MA34221B1 (es)
MX (1) MX338981B (es)
NI (1) NI201200155A (es)
PE (1) PE20130199A1 (es)
PH (1) PH12012502044A1 (es)
SG (1) SG184529A1 (es)
TN (1) TN2012000473A1 (es)
TW (1) TW201142024A (es)
UY (1) UY33334A (es)
WO (1) WO2011128561A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023098A1 (fr) 1993-04-05 1994-10-13 Daikin Industries, Ltd. Fibre de polytetrafluoroethylene, materiau cotonneux contenant ladite fibre, et procede de production dudit materiau
CN103703021A (zh) * 2010-12-23 2014-04-02 赛诺菲 用于治疗肝癌的Robo1-Fc融合蛋白
BR112014016493A2 (pt) 2012-01-05 2021-08-10 Boston Medical Center Corporation sinalização slit-robo para diagnóstico e tratamendo de doença renal
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
EP3455243B1 (en) 2016-05-11 2021-03-24 Cytiva BioProcess R&D AB Separation matrix
EP3455240B1 (en) 2016-05-11 2025-01-01 Cytiva BioProcess R&D AB Method of storing a separation matrix
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN109311948B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 清洁和/或消毒分离基质的方法
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
JP7018458B2 (ja) 2017-06-02 2022-02-10 ファイザー・インク 組換えｒｏｂｏ２タンパク質、組成物、方法およびそれらの使用
WO2019038772A1 (en) 2017-08-24 2019-02-28 Bar-Ilan University ROUNDABOUT FAMILY RECEPTOR INHIBITORS (ROBO) AND CORRESPONDING USES THEREOF
US20220125879A1 (en) * 2019-02-27 2022-04-28 Daewoong Pharmaceutical Co., Ltd. Albumin-bound composition including lrrd2 of slit3 protein for prevention or treatment of bone-related diseases
WO2020219592A1 (en) * 2019-04-23 2020-10-29 The Regents Of The University Of California Compositions and methods useful in promoting milk production
WO2025056020A1 (zh) * 2023-09-14 2025-03-20 北京拓界生物医药科技有限公司 包含robo结构域的蛋白及其医药用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
DE69816467T2 (de) * 1997-10-20 2004-04-15 The Regents Of The University Of California, Oakland Robo: eine familie polypeptiden und nukleinesäuren wirksam in nervenzellleitung
EP1071705A2 (en) 1998-04-02 2001-01-31 Rigel Pharmaceuticals, Inc. Peptides causing formation of compact structures
CA2416732C (en) * 2000-08-02 2016-02-09 Brad St. Croix Endothelial cell expression patterns
ES2431040T3 (es) 2002-03-08 2013-11-22 Shanghai Institutes For Biological Sciences, Cas Detección y modulación de la angiogénesis mediada por Slit y Roundabout (Robo), y sus usos
JP4643450B2 (ja) * 2003-08-08 2011-03-02 株式会社ペルセウスプロテオミクス 癌高発現遺伝子
AU2005207960A1 (en) * 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for the treatment of infertility
NZ611859A (en) * 2006-04-05 2014-12-24 Abbvie Biotechnology Ltd Antibody purification
PE20081250A1 (es) 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
EP2599791A1 (en) * 2007-04-27 2013-06-05 Genentech, Inc. Potent, stable and non-immunosuppressive anti-CD4 antibodies
MY159201A (en) 2007-08-29 2016-12-30 Sanofi Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof

Also Published As

Publication number Publication date
NI201200155A (es) 2013-02-05
MX2012011822A (es) 2012-11-12
MA34221B1 (fr) 2013-05-02
CL2012002879A1 (es) 2013-03-22
AU2011239839A1 (en) 2012-11-08
CN102884076A (zh) 2013-01-16
EP2558489A1 (fr) 2013-02-20
CA2796303A1 (fr) 2011-10-20
JP2013523172A (ja) 2013-06-17
JP5858442B2 (ja) 2016-02-10
IL222382A (en) 2016-06-30
ECSP12012230A (es) 2012-11-30
IL222382A0 (en) 2012-12-31
FR2958936A1 (fr) 2011-10-21
CR20120508A (es) 2012-11-01
US9493529B2 (en) 2016-11-15
TN2012000473A1 (fr) 2014-01-30
PE20130199A1 (es) 2013-03-09
MX338981B (es) 2016-05-06
WO2011128561A1 (fr) 2011-10-20
EA201291044A1 (ru) 2013-04-30
AU2011239839B2 (en) 2015-08-20
SG184529A1 (en) 2012-11-29
KR20130059329A (ko) 2013-06-05
BR112012026020A2 (pt) 2016-06-28
AR080891A1 (es) 2012-05-16
US20130039912A1 (en) 2013-02-14
DOP2012000265A (es) 2013-02-28
TW201142024A (en) 2011-12-01
PH12012502044A1 (en) 2017-07-26
UY33334A (es) 2011-12-01

Similar Documents

Publication Publication Date Title
GT201200275A (es) Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
GT201400057A (es) 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
BR112012012918A2 (pt) agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes.
MX2014012381A (es) Terapia de combinacion para tratar cancer.
GT201200315A (es) Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunes y autoinmunes
IN2014MN02069A (es)
GT201200172A (es) Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cáncer y enfermedades inmunes
UA107814C2 (uk) Спірооксіндольні антагоністи мdм2
BR112016004095A2 (pt) administração de enzimas de empobrecimento de quinurenina para a terapia contra tumores
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
MX377781B (es) Composiciones y metodos para diagnostico y tratamiento del cancer.
BR112013016107A2 (pt) molécula dimérica, método de tratamento de câncer, composição farmacêutica e kit para o diagnóstico de uma patologia ou tumor mediado(a) por upar
CO6741197A2 (es) Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma
BR112015006656A8 (pt) composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos
EP3164412A4 (en) Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment
EA201500370A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ДВОЙНЫЕ АНГИОПОЭТИН-2/Dll4 СВЯЗЫВАЮЩИЕ АГЕНТЫ И АНТИ-VEGF-R АГЕНТЫ
BR112018006572A2 (pt) terapia de combinação racional para o tratamento de câncer
MX2018003308A (es) Suministro localizado de agente anti-fuctactico para tratamiento del cancer.
AR079052A1 (es) Tratamiento del accidente cerebrovascular isquemico agudo o sangrado intracraneal con activador tisular de plasminogeno (tpa) y eritropoyetina carbamilada
UY35921A (es) Necrostatina-1 y derivados como retardadores de la degeneración axonal
UA58006U (ru) Средство для лечения дерматологических заболеваний и комплексного оздоровления тканей и органов c усилением защитных свойств организма
CY1115840T1 (el) Παραγωγα ν-ακυλ-αμινοξεος για τη θεραπευτικη αγωγη παθησεων του δερματος οπως η κυτταριτιδα